** Shares of drugmaker Regeneron Pharmaceuticals REGN.O rise 2% to $606 premarket
** REGN says it has agreed to buy bankrupt genetic testing firm 23andMe Holding for $256 million
** The agreement excludes the purchase of 23andMe's telehealth service Lemonaid Health
** 23andMe's bankruptcy proceedings had drawn scrutiny from lawmakers who warned that genetic data of millions of customers could be sold to unscrupulous buyers
** Regeneron says it will comply with 23andMe's privacy policies and applicable laws with respect to the use of customer data and that it is ready to detail its intended use of the data to a court-appointed overseer
** As of last close, REGN down 16.6% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。